Hematology - European Medical Journal

Continue

Hematology

Filter
4 Mins
28 Mar 2022

IMRT/IGRT Helical Tomotherapy Treatment in β-Thalassaemia

The following highlights focus on several insightful and innovative abstracts at the European Hematology Association (EHA) 2022 hybrid…
10 Mins
22 Mar 2022

Targeting the Immune System and Beyond: The Potential for Safe and Durable Responses in Higher-Risk Myelodysplastic Syndromes with Immuno-Myeloid Therapy

The hypomethylating agents (HMA), azacitidine and decitabine, are currently regarded as the standard of care for patients with…
13 Mins
18 Mar 2022

The Future of Gene Therapy for Haemophilia A and B: Innovative Treatment Management Strategies, Perspectives, and Updated Trial Results

Monogenic diseases such as haemophilia A and B are inherited conditions arising from mutations in a single gene. One defective gene leads…
EMJ
9 Mins
21 Feb 2022

The Search for Sustained Durability in Higher-Risk Myelodysplastic Syndrome: New Treatment Pathways in Sight

Higher-risk MDS is a collective term based on the Revised International Prognostic Scoring System (IPSS-R) that encompasses…
4 Mins
3 Feb 2022

Digital Necrosis in Multiple Myeloma

Multiple myeloma (MM) is a B cell malignancy characterised by abnormal proliferation of plasma cells that expand in the bone marrow…
12 Mins
31 Jan 2022

Updates on Isatuximab in Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

In the past decade, therapies that are more effective and less toxic have transformed the treatment landscape for patients with MM…
6 Mins
24 Jan 2022

Atorvastatin, Aspirin, and Hydroxyurea Treating Polycythaemia Vera

The following highlights focus on several insightful and innovative abstracts at the European Hematology Association (EHA) 2022 hybrid…
9 Mins
15 Dec 2021

Optimising Outcomes in Cutaneous T Cell Lymphoma: Role of Blood Involvement and Treatment Options

CTCL is a rare type of non-Hodgkin lymphoma, primarily presenting in the skin but with extracutaneous involvement in some patients. Around…
We’ve noticed you’re accessing
from North/South America.